Inovio Pharmaceuticals (INO) Equity Income (2011 - 2018)
Inovio Pharmaceuticals (INO) posted Equity Income of $228665.0 for Q3 2018, down 12.04% sequentially from $259971.0 in Q2 2018, and down 45.98% YoY from $423296.0 in Q3 2017.
Inovio Pharmaceuticals (INO) Equity Income (2011 - 2018) Analysis & Trends
Inovio Pharmaceuticals has reported Equity Income for 8 years, with the latest figure at $228665.0 in Q3 2018.
- Quarterly Equity Income fell 45.98% year-over-year to $228665.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was $228665.0 (down 79.85% YoY) and the FY2018 annual result came in at $360795.0, down 55.28% from the prior year.
- Equity Income eased to $228665.0 in Q3 2018 per INO's latest filing, from $259971.0 in the prior quarter.
- Over five years, Equity Income peaked at $824390.0 in Q2 2014 and troughed at -$505926.0 in Q1 2014.
- A 5-year average of $95835.4 and a median of $2690.0 in 2016 frame the typical range for Equity Income.
- The sharpest annual moves came in 2016 and 2017: Equity Income tumbled 33009.13% in 2016, then soared 15635.91% in 2017.
- Over 5 years, Equity Income stood at $143659.0 in 2014, then sank by 302.09% to -$290316.0 in 2015, then jumped by 322.13% to $644888.0 in 2016, then retreated by 10.13% to $579546.0 in 2017, then plunged by 60.54% to $228665.0 in 2018.
- According to Business Quant data, Equity Income over the past three periods registered $228665.0, $259971.0, and -$127841.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.08 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 228,665.00 |
| Jun 30, 2018 | 259,971.00 |
| Mar 31, 2018 | -127,841.00 |
| Dec 31, 2017 | 579,546.00 |
| Sep 30, 2017 | 423,296.00 |
| Jun 30, 2017 | -312,500.00 |
| Mar 31, 2017 | 116,477.00 |
| Dec 31, 2016 | 644,888.00 |
| Sep 30, 2016 | 2,690.00 |
| Jun 30, 2016 | -113,775.00 |
| Mar 31, 2016 | -406,249.00 |
| Dec 31, 2015 | -290,316.00 |
| Sep 30, 2015 | 518,877.00 |
| Jun 30, 2015 | -49,773.00 |
| Mar 31, 2015 | -1,227.00 |
| Dec 31, 2014 | 143,659.00 |
| Sep 30, 2014 | -113,980.00 |
| Jun 30, 2014 | 824,390.00 |
| Mar 31, 2014 | -505,926.00 |
| Dec 31, 2013 | -6.05 Mn |